Eli Lilly & Co. 2002 Annual Report (10-K) Summary
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 2002. Eli Lilly and Company is a global pharmaceutical firm incorporated in Indiana, operating primarily in a single significant business segment: pharmaceutical products. The company discovers, develops, manufactures, and sells products in approximately 150 countries. Key product categories include neuroscience (e.g., Zyprexa, Prozac), endocrine (e.g., Humalog, Actos), oncology (Gemzar), and animal health. As of February 18, 2003, the company had approximately 1.12 billion shares of common stock outstanding with an aggregate market value of roughly $55.7 billion.
Key Financial Metrics
Note: Specific revenue, profit, cash flow, and margin figures for 2002 are incorporated by reference from the 2002 Annual Report to Shareholders (Exhibit 13) and are not explicitly detailed in the provided text. The following metrics are available from the filing text:
- Research and Development (R&D) Expenses: $2.15 billion for 2002 (compared to $2.24 billion in 2001 and $2.02 billion in 2000).
- Employee Count: Approximately 43,700 total employees at year-end 2002, including 8,325 in R&D and 18,750 outside the United States.
- Major Customers: Three U.S. wholesale distributors (AmerisourceBergen, Cardinal Health, and McKesson) each accounted for between 16% and 17% of worldwide consolidated net sales in 2002.
- Debt Instruments: The company has registered various notes, including 8-3/8% Notes due 2006, 6.57% Notes due 2016, 7-1/8% Notes due 2025, and 6.77% Notes due 2036.
Material Changes and Operational Highlights
- New Product Approvals: Strattera (for ADHD) and Forteo (for osteoporosis) received U.S. approval in late 2002.
- Manufacturing and Quality: The FDA issued a warning letter in 2001 regarding current good manufacturing practices (cGMP) at Indianapolis facilities. While subsequent inspections in 2002 noted improvements, the FDA had not yet cleared all operations as of the filing date. Approval for Zyprexa IntraMuscular and Cymbalta remains contingent on resolving these manufacturing issues.
- Executive Leadership: Sidney Taurel serves as Chairman, President, and CEO. Charles E. Golden is the Executive Vice President and CFO. Robert A. Armitage joined as Senior Vice President and General Counsel in January 2003.
Outlook, Risks, and Contingencies
Legal Proceedings and Litigation:
- Patent Challenges: The company is engaged in significant litigation regarding Paragraph IV certifications for Zyprexa (trial scheduled for Jan 2004) and Evista (trial scheduled for Feb 2005). An unfavorable outcome could materially adversely impact operations and liquidity.
- Product Liability: Lilly is a defendant in approximately 105 actions regarding diethylstilbestrol (DES) and over 200 actions regarding thimerosal (alleged link to autism). The company strongly denies liability in thimerosal cases, noting it discontinued manufacturing the raw material in 1974.
- Regulatory Investigations: The company is responding to a DOJ grand jury subpoena regarding the marketing of Evista (alleged off-label promotion) and an FTC antitrust investigation into rebate practices.
Market and Regulatory Risks:
- Pricing Pressure: The company anticipates increasing pricing pressures in the U.S. due to Medicare reform debates, state Medicaid rebate programs, and potential importation of drugs from Canada.
- Intellectual Property: Patent expirations for key products (e.g., Zyprexa in 2011, Humalog in 2013) pose long-term risks to market exclusivity.
- Manufacturing Constraints: Complex production processes mean that plant shutdowns or supply interruptions could lead to product shortages.
Investor Verification Checklist
- Financial Statements: Review the 2002 Annual Report to Shareholders (Exhibit 13) for specific revenue, net income, and cash flow figures not detailed in this 10-K text.
- Manufacturing Status: Monitor FDA communications regarding the resolution of cGMP deficiencies at Indianapolis facilities, as this impacts the approval of Zyprexa IntraMuscular and Cymbalta.
- Patent Litigation Outcomes: Track the progress of the Zyprexa and Evista patent infringement trials scheduled for 2004 and 2005, respectively.
- Regulatory Investigations: Watch for updates on the DOJ investigation into Evista marketing practices and the FTC antitrust inquiry.
- R&D Pipeline: Assess the progress of late-stage investigational compounds for erectile dysfunction, depression, and cancer mentioned in the filing.